AbbVie released interim Phase III data for its calcitonin gene-related peptide receptor blocker Qulipta (atogepant), which demonstrated long-term safety and efficacy for patients in preventing chronic and episodic migraine.
Tag Archive for: migraine treatment
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
